Takeda reports Phase III AETHERA clinical trial data from ADCETRIS® at ASH annual meeting
Takeda UK Ltd reports data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology Oncology antibody-drug conjugate autologous stem cell transplant brentuximab vedotin Hodgkin lymphoma Latest News systemic anaplastic large cell lymph Source Type: news
More News: Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Lymphoma | Stem Cell Therapy | Stem Cells | Transplants